NRX Pharmaceuticals ( (NRXP) ) just unveiled an update.
NRx Pharmaceuticals announced its financial results for the fourth quarter and full year 2024, highlighting significant advancements in its drug development and corporate strategy. The company initiated the filing of a New Drug Application for NRX-100 for suicidal depression and plans to file for NRX-101 for bipolar depression. Additionally, NRx Pharmaceuticals is negotiating licensing agreements for NRX-100 and pursuing acquisitions to establish a national network of interventional psychiatry centers. These efforts aim to strengthen the company’s position in the mental health treatment market and potentially increase its profitability by the end of 2025.
More about NRX Pharmaceuticals
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. The company’s primary products include NRX-100, an intravenous ketamine for suicidal depression, and NRX-101, an oral medication for bipolar depression in patients at risk of akathisia. NRx Pharmaceuticals is working on expanding its market presence through strategic partnerships and acquisitions in the interventional psychiatry sector.
YTD Price Performance: -27.09%
Average Trading Volume: 1,208,455
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $37.21M
See more data about NRXP stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com